Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
Nafazatrom is an antithrombic drug that has been shown to have beneficial effects in traumatic shock and organ ischemia. This study evaluated the effect of nafazatrom on cardiovascular, sympathetic, and endocrine consequences to moderate or severe hemorrhagic shock in the conscious rat. Nafazatrom (2 mg/kg, i.v.) had no effect on the blood pressure, heart rate, and circulatory norepinephrine, vasopressin, and leukotriene C4 responses to bleeding. Nafazatrom significantly reduced plasma TXB2 and 6-keto-PGF1 alpha and blocked the increment in these cyclooxygenase metabolites in response to hemorrhage. It is concluded that nafazatrom does not increase survival after moderate hypovolemic hypotension and decreases survival to severe hemorrhage. Nafazatrom does not modify the cardiovascular, sympathetic, and neuroendocrine responses to hypovolemic hypotension.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004837:Epinephrine / Q000097:blood; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D009638:Norepinephrine / Q000097:blood; D011720:Pyrazoles / Q000627:therapeutic use*; D047069:Pyrazolones; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000097:blood; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000503:physiopathology; D013929:Thromboxane B2 / Q000097:blood
D005343:Fibrinolytic Agents; D011720:Pyrazoles; D047069:Pyrazolones; D013189:SRS-A; D001127:Arginine Vasopressin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C018845:nafazatrom; D009638:Norepinephrine; D004837:Epinephrine